Gastric cancer is the second cancer causing death worldwide. Both incidence and mortality rates vary according to geographical regions. The receptor for urokinase plasminogen activator (uPAR) is involved in extracellular matrix degradation by mediating cell surface associated plasminogen activation, and its presence on gastric cancer cells is linked to micrometastasis and poor prognosis. Immunohistochemical analyses of a set of 44 gastric cancer lesions from Costa Rica showed expression of uPAR in cancer cells in both intestinal subtype (14 of 27) and diffuse subtype (10 of 17). We compared the expression pattern of uPAR in gastric cancers from a high-risk country (Costa Rica) with a low-risk country (Norway). We found uPAR on gastric cancer cells in 24 of 44 cases (54%) from Costa Rica and in 13 of 23 cases (56%) from Norway. uPAR was seen in macrophages and neutrophils in all cases. We also examined the nonneoplastic mucosa and found that uPAR was more frequently seen in epithelial cells located at the luminal edge of the crypts in cases with Helicobacter pylori infection than in similar epithelial cells in noninfected mucosa (p 5 0.033; v 2 5 4.54). In conclusion, the expression of uPAR in cancer cells in more than half of the gastric cancer cases suggests that their uPAR-positivity do not contribute to explain the different mortality rates between the 2 countries, however, the actual prevalence of uPAR-positive cancer cells in the gastric cancers may still provide prognostic information.
Gastric cancer is the second most common cancer causing death worldwide after lung cancer and is a final result of the stepwise process initiated by environmental factors including diet and Helicobacter pylori infection. [1] [2] [3] In particular, H. pylori infection is one of the most recognized risk factors for this malignancy. [4] [5] [6] Both the incidence and mortality rates of gastric cancer present substantial variations according to geographical regions (between and within countries). 1 The factors explaining these variations remain unknown so far given the complexity and multifactorial nature of the disease. Costa Rica is one of the countries with highest incidence and mortality rates for gastric cancer worldwide. In contrast, most of western European countries present low incidence and low mortality rates for this malignancy. 1, 7 Among the key events for cancer development and progression are neoplastic cell invasion into the adjacent normal tissue and eventually metastasis. Invasion and metastasis are facilitated by a number of proteinases capable of degrading the extracellular matrix (ECM). 8, 9 Plasmin can degrade major ECM proteins like fibrin, fibronectin and laminin and in addition can activate other matrix degrading proteinases. Plasmin is formed on cell surfaces after proteolytic cleavage of its zymogen plaminogen by urokinase-type plasminogen activator (uPA). 10 uPA mediates plasminogen activation after binding with high affinity to its specific receptor (uPAR), a 3-domain GPI-linked cell surface protein. 11 uPAR is predominantly seen on inflammatory cells and to a lesser extent on cancer cells in areas of cancer invasion in several types of cancer including gastric, colon, breast and oral cancer. [12] [13] [14] [15] [16] [17] In gastric cancer lesions, uPAR expression has been observed in macrophages, endothelial cells and cancer cells located at the invasive front of the tumors. 15, 18, 19 Increased expression of uPAR antigen or mRNA in tissue extracts and blood from patients with gastric cancer have been associated with some clinico-pathological aspects of the disease including poor prognosis. [18] [19] [20] [21] [22] [23] [24] [25] [26] Interestingly, studies in bone marrow aspirates from curatively resected patients with gastric cancer show that those cases with uPAR-positive cancer cells disseminated into the bone marrow have worse prognosis than patients with disseminated uPAR-negative cancer cells. [27] [28] [29] A significant association between high expression levels of uPAR in primary tumors and uPAR-positive disseminated tumor cells was also reported. 30 These observations suggest that elevated expression of uPAR in tumors and particularly in cancer cells may be an indication of more aggressive gastric cancers. Therefore, uPAR expression in cancer cells may represent an important prognostic marker for patients with gastric cancer. In addition, studies in gastric cancer cell lines have reported increased uPAR mRNA levels when neoplastic cells are cocultured with H. pylori, 31, 32 suggesting that H. pylori may induce the expression of uPAR in gastric mucosa. This may link uPAR with early steps of gastric carcinogenesis, which contributes to explain the association between H. pylori and gastric cancer and the correlation observed between the incidence rates of this malignancy and the prevalence of the bacterium. 33 This study has been conducted to compare the expression and presence of uPAR in gastric cancer cells in cases from high-and low-risk countries (Costa Rica and Norway, respectively) and to explore the possible connection between uPAR expression in gastric mucosa and H. pylori infection.
Material and Methods

Tissue samples
Formalin-fixed and paraffin-embedded gastric cancer tissue (neoplastic and nonneoplastic) were obtained postoperatively from 44 gastric cancer cases in 2 hospitals in Costa Rica (Max Peralta Hospital and Rafael Angel Calderón Guardia Hospital) and 23 cases from Bergen, Norway (Haukeland University Hospital). Histopathological information was collected from all the 67 cases. This histopathological classification was given according to the Laurén Classification System (Norwegian cases) and Japanese Classification System (Costa Rican cases). For the purposes of this study, Costa Rican cases were reclassified according to Laurén Classification System following established criteria given by the Japanese Gastric Cancer Association. 34 
Antibodies
Affinity purified monoclonal antibodies (clones R2 and R4) and rabbit polyclonal antibodies (pAbs) against human uPAR have been described previously. 35, 36 mAbs against cytokeratin-19 (clone RCK108), cytokeratins (clones AE1/AE3), CD68 (clone KP1), rabbit pAbs against H. pylori (code no. B0471), FITC-conjugated goat anti-mouse IgG and nonimmune rabbit IgG were purchased from Dako (Glostrup, Denmark). FITC-conjugated goat anti-rabbit IgG, Cy3-conjugated goat anti-mouse and Cy3-conjugated goat anti-rabbit were obtained from Jackson Immunoresearch (West Grove, PA). Monoclonal antibody directed against trinitrophenyl hapten (TNP, IgG1) was previously described. 37 
Immunoperoxidase staining
Three to four micrometer paraffin-embedded tissue sections were deparaffinized with xylene and hydrated in gradual series of ethanol-water dilutions. For uPAR R2, uPAR pAb, both cytokeratins (CKs), anti-H. pylori and anti-TNP, sections were pretreated with Proteinase-K (10 lg/mL) for 25 min at 37 C. For R4 immunohistochemistry, sections were heat-treated in a T/T Micromed microwave processor (Milestone, Sorisol, Italy) at 98 C for 15 min in target retrieval solution (code no. S1699 pH 6.0; Dako). Endogenous peroxidase activity was blocked by incubation in 1% hydrogen peroxide solution for 15 min. The primary antibodies were diluted in antibody diluent (Dako) and incubated for 2 hr in Shandon racks (Thermo Shandon, Pittsburg, PA) at the following dilutions: uPAR R2 0.9 lg/mL, uPAR R4 5.1 lg/mL, uPAR pAb 1.8 lg/mL, CKs 1:300, anti-H. pylori 1:150. Subsequently, the primary antibodies were detected with EnVision reagent, either anti-mouse IgG or anti-rabbit IgG horseradish peroxidase-conjugated polymers (Dako). The reactions were visualized by incubating the sections with NovaRED (Vector Laboratories, Burlingame, CA) or DAB Chromogen (Dako) (for H. pylori pAbs) according to manufacturer's instructions and counterstained with Mayer's haematoxylin.
Negative controls
The sections were pretreated in the same way as previously described for all the antibodies. The polyclonal anti-uPAR was substituted with normal rabbit immunoglobulin (code No. X903 Dako) incubated in an Ig concentration equivalent to that used for the specific primary antibody. Monoclonal antibodies R2 and R4 were substituted with anti-TNP mAb incubated at the same concentrations as those for R2 and R4.
Immunofluorescence staining
For the double immunofluorescence analyses, sections were initially processed as mentioned earlier for uPAR pAbs, using proteinase-K pre-treatment. uPAR pAbs (2.4 lg/mL) were diluted in Dako antibody diluent and incubated 2 hr at room temperature, together with a mixture of mouse monoclonal antibodies against CK-19 and CK AE1/AE3 (CKs, 1:300). The uPAR pAb was detected with Cy3-conjugated goat antirabbit IgG, 1:200 and the mixture of monoclonal antibodies against CKs with FITC-conjugated goat anti-mouse IgG, 1:200. To carry out double staining for uPAR and H. pylori, the sections were heat-treated by using target retrieval solution (code no. S1699 pH 6.0; Dako). The monoclonal antiuPAR R4 (5.1 lg/mL) was diluted in antibody diluent (Dako) together with anti-H. Pylori pAbs (1:150) and incubated on the tissue sections for 2 hr at room temperature. The antibodies were subsequently detected with Cy3-conjugated goat-antimouse IgG, 1:200 and FITC-conjugated goat anti-rabbit IgG, 1:200, respectively. After brief rinses with TBS, the sections were mounted with Prolong Gold antifade (Molecular Probes, Eugene, OR).
For the triple immunofluorescence analyses, Zenon antibody-labelling technology (Molecular Probes, Eugene, OR) was applied, following the manufacturer's instructions. Briefly, sections were heat-treated with target retrieval solution (code no. S1699 pH 6.0; Dako) as described mentioned. Anti-CD68 (clone KP1 and IgG1) was linked to Zenon 647 IgG1 according to the manufacturer's instructions, complexed anti-CD68 and mixed with uPAR pAbs (2.4 lg/mL) diluted in antibody diluent (Dako). The mix of the 2 antibodies was added to the sections and incubated 2 hr at room temperature. After washing with TBS, uPAR pAbs were detected with Cy3-conjugated goat anti-rabbit (1:200). Subsequently, CKs (clones AE1/AE3) was linked to Zenon 488 IgG1 according to the manufacturer's instructions and incubated on the tissue sections overnight at 4 C. Finally, tissue sections were washed with TBS and mounted with Prolong Gold antifade (Molecular Probes, Eugene, OR).
Confocal Microscopy
The double and triple stained sections were analyzed using a confocal laser-scanning microscope, LSM 510 META (Carl Zeiss, Jena, Germany) equipped with a 488 nm Argon laser, a 543 nm HeNe1 laser and a 633nm HeNe2 laser. The images were obtained using the lambda mode (pinhole diameter 135 lm) collecting fluorescent signals from 509 to 595 nm wavelength (double staining) or 509-691 nm wavelength (triple staining). For separation of the specific fluorescence signals, we first obtained FITC, Cy3, Alexa fluor 647 and erythrocyte autofluorescence emission spectra from single-fluorophore stained sections. From double-and triple-labeled sections, the collected fluorescence signal was separated by the emission fingerprinting using the above emission spectra to separate the individual fluorescence signals as described. 38 Nomarsky differential interference contrast (phase image technique) was used to show the tissue structures revealed by refractive index inhomogeneities.
Scoring for the immunoperoxidase stainings
The sections stained for R2 mAb and uPAR pAbs were evaluated by 2 independent investigators. uPAR immunoreactivity in cancer cells was scored based on the estimated percentage of positive cells seen in the whole section. Thus, the percentage of positive cancer cells were grouped into the following categories: 0, (no uPAR positive cancer cells detected); 1, less than 1% positively stained cancer cells (some few observed at the invasive edges of the tumor); 2, between 1 and 5% positive cancer cells; 3, between 5 and 10% positive cancer cells and 4, more than 10% positively stained cancer cells (Fig. 2) .
H. pylori immunoreactivity was scored based on the density of bacteria and the number of crypts containing bacteria into the following categories: À, no evidence of H. pylori on the section; þ, less than 3 crypts with small clusters of bacteria; þþ, either less than 3 crypts with dense clusters of bacteria or more than 3 crypts with small clusters and þþþ, 3 or more crypts with dense clusters of bacteria (Figs. 4h and 4i) .
To assess the relation between uPAR expression in epithelial cells and H. pylori infection, tissue sections from adjacent normal nonneoplastic gastric mucosa stained for R2 mAb were evaluated independently by 2 investigators. This evaluation was blinded regarding the H. pylori status and was based on the estimated percentage of crypts showing uPAR-positive epithelial cells (Fig. 4c) as follows:0, 0-5% positive crypts; 1þ, 5-30% positive crypts; 2þ, 30-60% positive crypts and 3þ, more than 60% positive crypts.
Statistical analysis v
2 analysis was performed to evaluate the possible differences regarding: the frequency of cases having uPAR-positive cancer cells between Costa Rican and Norwegian cases, the frequency of cases having uPAR-positive cancer cells in intestinal versus diffuse subtypes, the H. pylori positivity between the 2 countries and the association between uPAR expression in gastric epithelial cells and H. pylori infection. The association between uPAR immunoreactivity in cancer cells and UICC stage was assessed by v 2 statistics of exact probabilities. p ¼ 0.05 was considered statistically significant in all cases.
Results
uPAR expression in intestinal and diffuse subtypes of gastric cancer
Immunoperoxidase staining for uPAR in both intestinal and diffuse histological subtypes revealed uPAR expression in all the 44 cases (Costa Rica). In gastric cancers of intestinal subtype, uPAR was mainly seen in the stroma along the invasive front of the tumors (Figs. 1a and 1c) with the most intense signal being observed in areas with abundant invasion of neoplastic single cells (Figs. 1a and 1b) . In contrast, in gastric cancer of diffuse subtype the uPAR-positive cells were seen both in the invasive front and in central areas of the tumors as single cancer cells and/or small clusters of cancer cells (Fig. 1d) . The expression of uPAR in various cell types along the invasive front in both intestinal and diffuse subtype was histologically complex, but at the general level the uPAR-positive cells included cancer cells, macrophages and neutrophils (Figs. 1a, 1c, and 1f) . In some cases, positive fibroblasts and nerve bundles were also observed (not shown). In 7 cases with intramucosal carcinoma, all of them intestinal subtype, uPAR staining was seen in the adjacent stroma, suggesting that uPAR is upregulated early during gastric cancer development (Fig. 1e) .
The specificity of the uPAR immunoreactivity was based on the analysis of a series of positive and negative controls. An identical uPAR staining pattern was obtained with 3 different anti-uPAR antibodies (R2, R4 and pAbs) in 28 gastric cancer cases (Figs. 1g and 1h) . As negative controls, we substituted R2 and R4 uPAR mAbs with a mAb against TNP and the uPAR pAbs with normal rabbit immunoglobulin. No specific staining was obtained with these 2 antibodies when incubated at similar immunoglobulin concentrations as the respective anti-uPAR antibody preparations (Fig. 1i) .
uPAR is expressed in gastric cancer cells in both intestinal and diffuse subtypes Our immunoperoxidase staining suggested that uPAR-positive cancer cells are present in both intestinal (Figs. 2a-2d ) and diffuse subtype of gastric cancer (Figs. 2e-2i ). To further substantiate this observation, immunoflourescence analyses for uPAR in combination with CKs and/or CD68 were performed in a subset of 9 cases, from both histological subtypes, with particularly complex uPAR expression pattern. In intestinal subtype, uPAR was present in both CK-positive cancer cells and in adjacent CD68-positive macrophages (Figs. 3a-3c ), whereas uPAR in diffuse subtype was predominantly seen in CK-positive cancer cells (Figs. 3d-3f) . Table 1 ). Because gastric cancer incidence and mortality rates markedly vary depending on geographical location, 7 we then compiled a series of 23 cases from the low risk country (Norway) with a similar distribution of intestinal and diffuse subtype cases as compared to the Costa Rican series. We tested whether the frequency of uPAR-positive cancer cells was similar to that in the Costa Rican material (Table 1 ). In general, 
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H. pylori associates with the induction of uPAR in gastric mucosa
Analysis of uPAR expression in non-neoplastic mucosa with some degree of inflammation showed uPAR immunoreactivity in gastric epithelial cells located toward the gastric lumen in the Costa Rican material (Figs. 4a and 4d) . Because a possible relation between H. pylori and induction of uPAR expression in gastric cancer cells has been suggested, 30, 32 we explored the possibility that uPAR is upregulated in gastric epithelium as a consequence of H. pylori infection. Samples from nonneoplastic mucosa were stained for H. pylori. Immunoperoxidase staining showed H.pylori in 77% (34 of 44) of the Costa Rican and 30% (7 of 23) of the Norwegian cases (p ¼ 0.00021; v 2 ¼ 13.71). H. pylori clusters were observed at the luminal space of the crypts, in direct contact with epithelial cells of the surface and deeper areas of the crypts, and inside some of the mucosal glands (Figs. 4e and 4f) , with the highest density of bacteria in foci of gastritis-affected mucosa (Fig. 4f) . Immunoperoxidase staining for uPAR in adjacent tissue sections of non-neoplastic mucosa from the 23 Norwegian cases (Table 2) , showed expression of uPAR in surface epithelial cells located toward the gastric lumen, similar to our observation in the Costa Rican material (Figs. 4a-4d) . The presence of uPAR on surface epithelial cells was significantly associated with the presence of H. pylori (p ¼ 0.033; v 2 ¼ 4.54). Indeed, double immunofluorescence analysis for uPAR and H. pylori in tissue sections of non-neoplastic tissue adjacent to the neoplastic growth from 8 of the patients with gastric cancer from Costa Rica (5 H. pylori-positive and 3 H. pylori-negative), showed intense uPAR immunoreactivity in surface epithelial cells located at the luminal edge of the crypts that were in direct contact with bacteria in the H. pylori-positive patients (Figs. 4h and 4i ). In contrast, the H. pylori-negative cases showed no or weak uPAR expression in epithelial cells at similar location (not shown).
Discussion
In this study, we show that uPAR is expressed in a part of cancer cells in approximately 50% of all gastric cancers in both high-and low-risk countries. Our findings suggest the further evaluation of uPAR as a potential immunohistochemical parameter, which, based on the prevalence of uPAR-positive cancer cells in the tumor, may provide prognostic information about the patient. Our observations are based on immunohistochemical analyses of 2 uPAR mAbs (R2 and R4) directed against 2 different domains on uPAR, and a preparation of affinity purified polyclonal antibodies against uPAR. 35, 36 The 3 different antibody preparations identified uPAR on gastric cancer cells and stromal cells to the same extent, while a mAb directed against the TNP hapten or non-immune rabbit IgG showed no specific staining. We therefore conclude that the uPAR staining observed represent the genuine uPAR protein.
The assumption that uPAR-positive gastric cancer cells are of particular aggressive character is based on analyses of Cases with uPAR þ cancer cells 24 13 37
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micro-metastatic cells identified in bone marrow aspirates from patients with gastric cancer, 27 and its significant association with survival. 29 We found uPAR-positive gastric cancer cells with the same frequency in intestinal and diffuse subtypes. In their study, Heiss et al. 29 found no significant correlation between the presence of uPAR-positive micro-metastatic cells in bone marrow aspirates and Laurén's classification, meaning that these cells were observed with similar frequency in both intestinal and diffuse subtype. Thus, an accurate determination of the prevalence of uPARpositive gastric cancer cells by immunohistochemistry could be of fundamental importance owing to its potential prognostic significance and the repercussions that this may have for 15 and ours is the proteolytic pre-digestion step. Migita et al. 15 used trypsin, whereas we used proteinase-K. Epitope demasking is a crucial step for most immunohistochemical analyses. We have observed that the efficiency of the proteolytic predigestion strongly influence the intensity of uPAR immunoreactivity (Alpízar-Alpízar and Nielsen, unpublished observations). It cannot be excluded, however, that geographical differences could explain the differences (see also below). Kawasaki et al. 19 used in situ hybridization and found uPAR mRNA expression in cancer cells in both intestinal and diffuse subtypes (5 of 33 cases and 14 of 58 cases, respectively).
The strongest contribution to uPAR immunoreactivity in the gastric cancer samples was in general the stromal cell population, particularly the inflammatory cells, macrophages and neutrophils. These cell populations are generally found to be uPAR-positive in a number of tissue types. 14, 39 Immunohistochemical analysis of uPAR has therefore appeared to be quite complex; not only in gastric cancer but also in breast, oral and colon cancer, where double immunofluorescence analyses have been crucial for a sufficient discrimination of the different uPAR-positive cell populations. 12, 13, 16 uPAR-positive cancer cells are found in different types of carcinomas with varying occurrence including colon, breast and oral cancer. 12, 13, 16 In colon cancer, the uPAR-positive cancer cells are located at the invasive front 13, 40 as they also are in the gastric cancers of intestinal subtype ( 15 and this article), suggesting similar invasion mechanisms in these 2 gastrointestinal adenocarcinomas. Expression of uPAR in both cancer cells and stromal cells contribute to the total level of uPAR in the cancer tissue. However, it is currently unknown to which extent uPAR derived from the different cell populations contribute to the prognostic significance of uPAR and the uPAR degradation products that can be measured in blood and tissue extracts. 41 It is believed that uPAR expression on cells facilitate cell migration by interacting with extracellular matrix components like vitronectin, 42, 43 or with other cell surface associated proteins, like integrins. 44 Therefore, expression of uPAR on cancer cells is likely to enhance its potential to invade and metastasize. In a metastasis model, transgene overexpression of uPAR in tumor cells confers enhanced proliferative and metastatic potential dependent on the interaction of uPAR with integrins and fibronectin. [45] [46] [47] [48] [49] [50] These observations might explain the correlation found between the presence of uPARpositive micro-metastatic cancer cells in the bone marrow and poor prognosis in patients with gastric cancer. 29, 51 Hence, the clinical relevance of uPAR expression in neoplastic cells of gastric cancer may be based on its proinvasive, prometastastatic and proliferative properties.
Gastric cancer incidence presents important variations according to geographical regions. 1 The factors explaining these variations remain unknown so far given the complexity and multifactorial nature of the disease. These different incidence rates are likely to be explained by ethnical, environmental, cultural and socioeconomic aspects. For example, studies assessing the association between genetic polymorphisms of pro and anti-inflammatory cytokines and gastric cancer have shown different results depending on geographical regions. [52] [53] [54] Likewise, differences between H. pylori strains among geographical regions correlate well with the distribution of the gastric cancer incidence. 33 This suggests that when studying aspects potentially related with gastric cancer development and progression, geographical regions are important to take into account. In this study, we determined the expression of uPAR in cancer cells, in gastric cancer tissue obtained from a country with one of the highest gastric cancer incidence rates worldwide (Costa Rica) and one with low incidence rate (Norway). 7 We did however find similar frequency of uPAR-positive cancer cells in Costa Rican and Norwegian gastric cancer cases, suggesting that the expression of uPAR and its potential role in gastric cancer development and progression is independent of geographical, ethnical or environmental differences. Though, it cannot be excluded that gastric cancer developing in other geographical regions could present different uPAR expression patterns.
Another important finding in this study was the intense uPAR immunoreactivity in epithelial cells located at the luminal edge of the non-neoplastic mucosa. Epithelial cells at this location can, eventually, be in direct contact with H. pylori bacteria, and this organism is associated with several responses in the gastric mucosa. 55, 56 A semiquantitative analysis of H. pylori-positive cases and the presence of uPARpositive surface epithelium revealed a significant association, and indeed we found H. pylori clusters in close proximity to uPAR-positive surface epithelium by double immunofluorescence analysis. In vitro studies have shown increased levels of both uPAR mRNA and uPAR antigen when gastric cancer cell lines are challenged with H. pylori, 32, 57 and when cocultured with H. pylori cagA-positive versus negative strains. 31, 58 These observations taken together suggest that H. pylori may be directly involved in the induction of uPAR in the gastric mucosa. It is tempting to speculate that H. pylori can stimulate the expression of uPAR in epithelial cells, which under certain circumstances could potentiate the development of gastric pathological conditions that leads to gastric neoplasia. The findings in a mouse model where simultaneous transgene overexpression of uPAR and uPA in mouse skin confer a pathological epidermal phenotype 59 and the enhanced proliferation potential of uPAR-overexpressing transgenic cell lines, [45] [46] [47] [48] [49] [50] support this idea. The final outcome may, however, result from the interaction of uPAR with other molecules in the mucosal microenvironment including uPA, extracellular matrix proteins and mediators of inflammation released in response to H. pylori infection. Hence, the possible connection between H. pylori and uPAR and its potential implications in gastric cancer development and progression need to be further explored. These findings raise new and exciting questions regarding the role of H. pylori and uPAR in the development of gastric cancer, including elucidation of the role of the various H. pylori virulence factors in the induction of uPAR and the potential prognostic value of uPAR in gastric cancer.
